TRAILBLAZER-ALZ Trial Data Reveals Donanemab Effects in Early Alzheimer's: AAN 2025
At the 2025 American Academy of Neurology (AAN) Annual Meeting in San Diego, new data from the TRAILBLAZER-ALZ clinical trial program highlighted critical risk factors and management strategies for amyloid-related imaging abnormalities (ARIA) in patients with early symptomatic Alzheimer’s disease treated with donanemab.